Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and economic review of erlotinib in non-small-cell lung cancer.

Expert review of pharmacoeconomics & outcomes research - 1 Aug 2012

Yeung Kai, Carlson Josh J

Abstract excerpt

Lung cancer has the highest incidence and mortality among cancers of both men and women. Treatment strategies for non-small-cell lung cancer, the most common form of lung cancer, continue to evolve, most recently with the positive trial results for EGF receptor (EGFR) tyrosine kinase inhibitors in the first-line setting in molecularly targeted populations. Despite these promising findings, EGFR tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cost-Benefit Analysis
Share to Drug Costs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 22971028
DOI: 10.1586/erp.12.42

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and economic review of erlotinib in non-small-cell lung cancer.PMID 22971028Read ↗

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.Semantic proximity Read ↗

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.Semantic proximity Read ↗

Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review.Semantic proximity Read ↗

Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review.Semantic proximity Read ↗

A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.Semantic proximity Read ↗

The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.Semantic proximity Read ↗

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.Semantic proximity Read ↗

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.Semantic proximity Read ↗

Erlotinib in lung cancer.Semantic proximity Read ↗

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.Semantic proximity Read ↗

Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.